Andrés Pizzorno

I graduated with a License in Biochemistry from Universidad de la República (Uruguay) in 2008 and obtained my MSc. and PhD. in Microbiology-Immunology (2011 and 2015) from Laval University (Canada). Former fellow of the Knowledge Translation and Pandemic Preparedness Program of the PHAC-CIHR Influenza Research Network (Canada) during the 2009-11 influenza pandemic, my doctoral work focused on the mechanisms of antiviral resistance in influenza viruses and the evaluation of new combined therapies. Following a 3.5-year postdoc at the VirPath team and 3 years as R&D Manager for Signia Therapeutics SAS, I am currently Adjunct Investigator of the A*STAR ID Labs (Singapore) and tenured INSERM researcher at the CIRI - Team VirPath, where I lead an emerging group focused on the cellular and molecular aspects of virus-host and the pathophysiology of respiratory viral infections as the starting point for the development of innovative host-directed preventive and therapeutic approaches.